Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy - PubMed (original) (raw)

Clinical Trial

. 2004 Nov;20(11):1196-209.

doi: 10.1089/aid.2004.20.1196.

Affiliations

• PMID: 15588342
• DOI: 10.1089/aid.2004.20.1196

Clinical Trial

Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy

Jodi K Craigo et al. AIDS Res Hum Retroviruses. 2004 Nov.

Abstract

HIV-1 RNA levels in semen and blood compartments decrease below detection limits during highly active antiretroviral therapy. Despite these therapeutic effects, it is clear that persistent, latent HIV-1 reservoirs are capable of rebounding in the absence of drug treatment or by evolution of escape mutants remain. The current study was designed to examine the presence of latent virus in semen and blood compartments and its evolution following potent combination therapy with indinavir (protease inhibitor) and efavirenz [nonnucleoside reverse transcriptase (RT) inhibitor]. Using an ultrasensitive in situ hybridization assay HIV-1 mRNA was detected in cultured seminal and blood mononuclear cells in all patients up to 1789 days posttherapy. Higher levels of HIV-1 mRNA were consistently detected in seminal mononuclear cells as compared to peripheral blood mononuclear cells (PBMC) in all time points analyzed posttherapy. Analysis of viral RNA from cultured PBMC before and after therapy displayed no evidence of therapy-induced drug resistance in the viral polymerase gene in the majority of patients. However, distinct envelope populations were detected in these viral RNA populations following therapy, indicating possible selection of quasispecies. The observed ongoing replication and evolution in the PBMC viral envelope sequences likely occurred in the seminal compartment HIV populations, given that the seminal cells showed the ability to express HIV-1 mRNA following cultivation. This together with our previous studies (Gupta P, et al.: J Infect Dis 2000;182:79-87) suggest that the genital and blood compartments likely serve as distinct reservoirs harboring latent HIV-1 during prolonged drug therapy.

PubMed Disclaimer

Similar articles

• Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.
  Saitoh A, Hsia K, Fenton T, Powell CA, Christopherson C, Fletcher CV, Starr SE, Spector SA. Saitoh A, et al. J Infect Dis. 2002 May 15;185(10):1409-16. doi: 10.1086/340614. Epub 2002 Apr 30. J Infect Dis. 2002. PMID: 11992275 Clinical Trial.
• Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections.
  Nunnari G, Otero M, Dornadula G, Vanella M, Zhang H, Frank I, Pomerantz RJ. Nunnari G, et al. AIDS. 2002 Jan 4;16(1):39-45. doi: 10.1097/00002030-200201040-00006. AIDS. 2002. PMID: 11741161
• Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy.
  Zhang H, Dornadula G, Beumont M, Livornese L Jr, Van Uitert B, Henning K, Pomerantz RJ. Zhang H, et al. N Engl J Med. 1998 Dec 17;339(25):1803-9. doi: 10.1056/NEJM199812173392502. N Engl J Med. 1998. PMID: 9854115
• Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
  Van Vaerenbergh K. Van Vaerenbergh K. Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
• Pathophysiology of HIV-1 in semen: current evidence for compartmentalisation and penetration by antiretroviral drugs.
  Chan DJ. Chan DJ. Curr HIV Res. 2005 Jul;3(3):207-22. doi: 10.2174/1570162054368039. Curr HIV Res. 2005. PMID: 16022654 Review.

Cited by

• Compartmentalization of the gut viral reservoir in HIV-1 infected patients.
  van Marle G, Gill MJ, Kolodka D, McManus L, Grant T, Church DL. van Marle G, et al. Retrovirology. 2007 Dec 4;4:87. doi: 10.1186/1742-4690-4-87. Retrovirology. 2007. PMID: 18053211 Free PMC article.
• HIV-1 RNA may decline more slowly in semen than in blood following initiation of efavirenz-based antiretroviral therapy.
  Graham SM, Holte SE, Dragavon JA, Ramko KM, Mandaliya KN, McClelland RS, Peshu NM, Sanders EJ, Krieger JN, Coombs RW. Graham SM, et al. PLoS One. 2012;7(8):e43086. doi: 10.1371/journal.pone.0043086. Epub 2012 Aug 13. PLoS One. 2012. PMID: 22912795 Free PMC article.
• Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1.
  van Leeuwen E, Ter Heine R, van der Veen F, Repping S, Beijnen JH, Prins JM. van Leeuwen E, et al. Antimicrob Agents Chemother. 2007 Jan;51(1):335-7. doi: 10.1128/AAC.00774-06. Epub 2006 Oct 30. Antimicrob Agents Chemother. 2007. PMID: 17074793 Free PMC article. Clinical Trial.
• Genetic characterization of HIV-1 from semen and blood from clade C-infected subjects from India and effect of therapy in these body compartments.
  Shen C, Ding M, Craigo JK, Tarwater P, Chatterjee R, Roy P, Guha SK, Saha B, Modak D, Neogi D, Chen Y, Gupta P. Shen C, et al. Virology. 2010 Jun 5;401(2):190-6. doi: 10.1016/j.virol.2010.01.033. Epub 2010 Mar 15. Virology. 2010. PMID: 20231027 Free PMC article.
• Detection of Simian Immunodeficiency Virus in Semen, Urethra, and Male Reproductive Organs during Efficient Highly Active Antiretroviral Therapy.
  Matusali G, Dereuddre-Bosquet N, Le Tortorec A, Moreau M, Satie AP, Mahé D, Roumaud P, Bourry O, Sylla N, Bernard-Stoecklin S, Pruvost A, Le Grand R, Dejucq-Rainsford N. Matusali G, et al. J Virol. 2015 Jun;89(11):5772-87. doi: 10.1128/JVI.03628-14. Epub 2015 Apr 1. J Virol. 2015. PMID: 25833047 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • LANL HIV Databases